PPHM UPDATE

PPHM achieved full enrollment for its two-arm Phase 1B Trial combining Bavtuximab with Yervoy, an Anti CTLA-4 drug  for advanced melanoma in patients.

The trial is expected to take 12 - 14 weeks with data being possibly available in March 2016.

PPHM had done a pre-clinical trial involving mice and the data showed incredible proof of how Bavituximab could work with another immunotherapy drug to combat melanoma tumours.



The chart above exemplifies the efficacy of Bavituximab equivalent Ch1N11 (for mice) when used with Anti CTLA-4 in combating  melanoma tumours.

It shows how Ch1N11 (red colour) alone can handily beat Anti CTLA-4 (blue colour) and how the two combination (green colour) could be a potent mixture which surpassed in efficacy vs each stand alone drug on its own.

My disclosure: I own shares of PPHM.